Kala Pharmaceuticals EBITDA vs. Price To Sales
| KALA Stock | USD 6.91 0.11 1.62% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -36.1 M | Current Value -37.9 M | Quarterly Volatility 35.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.59 | 0.39 |
|
|
For Kala Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kala Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kala Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kala Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kala Pharmaceuticals over time as well as its relative position and ranking within its peers.
Kala |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.67) | Quarterly Revenue Growth (1.00) | Return On Assets (0.40) | Return On Equity (2.48) |
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kala Pharmaceuticals Price To Sales vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kala Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kala Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Kala Pharmaceuticals is rated below average in ebitda category among its peers. It is rated below average in price to sales category among its peers . At present, Kala Pharmaceuticals' EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kala Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Kala Price To Sales vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Kala Pharmaceuticals |
| = | (36.08 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Kala Pharmaceuticals |
| = | 1.16 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Kala Price To Sales Comparison
Kala Pharmaceuticals is currently under evaluation in price to sales category among its peers.
Kala Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kala Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kala Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Kala Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Kala Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 4.6 K | 4.8 K | |
| Operating Income | -39.2 M | -41.1 M | |
| Net Loss | -46.4 M | -48.7 M | |
| Income Before Tax | -42.2 M | -44.3 M | |
| Total Other Income Expense Net | -3 M | -2.9 M | |
| Net Loss | -40.3 M | -42.4 M | |
| Net Loss | -42.2 M | -44.3 M | |
| Income Tax Expense | -40.1 M | -38.1 M | |
| Interest Income | 2.5 M | 2.6 M | |
| Net Interest Income | -3.5 M | -3.6 M | |
| Change To Netincome | -42 M | -39.9 M | |
| Net Loss | (17.35) | (18.22) | |
| Income Quality | 0.66 | 0.74 | |
| Net Income Per E B T | 0.01 | 0.01 |
Kala Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kala Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kala Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kala Pharmaceuticals' important profitability drivers and their relationship over time.
Use Kala Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kala Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kala Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Kala Pharmaceuticals Pair Trading
Kala Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Kala Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kala Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kala Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kala Pharmaceuticals to buy it.
The correlation of Kala Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kala Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kala Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kala Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kala Pharmaceuticals position
In addition to having Kala Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
To fully project Kala Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Kala Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Kala Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.